NRX Pharmaceuticals (NRXP) Research & Development (2020 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Research & Development of $1.3 million for Q1 2026, up 62.81% year-over-year from $804000.0 in Q1 2025, and up 134.59% quarter-over-quarter from $558000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Research & Development (2020 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Research & Development for 7 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 62.81% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $4.3 million (down 18.5% YoY), while the FY2025 annual figure was $3.8 million, down 39.07% from the prior year.
- Research & Development improved to $1.3 million in Q1 2026 per NRXP's latest filing, from $558000.0 in the prior quarter.
- Across five years, Research & Development topped out at $5.5 million in Q1 2022 and bottomed at $558000.0 in Q4 2025.
- Historically, Research & Development has averaged $2.3 million across 5 years, with a median of $1.7 million in 2024.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 85.34% — and 2025, when it surged 133.88%.
- NRX Pharmaceuticals' Research & Development stood at $4.5 million in 2022, then sank by 43.13% to $2.5 million in 2023, then sank by 59.12% to $1.0 million in 2024, then slumped by 46.14% to $558000.0 in 2025, then surged by 134.59% to $1.3 million in 2026.
- Business Quant data shows NRXP's Research & Development at $1.3 million in Q1 2026, $558000.0 in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.31 Mn |
| Dec 31, 2025 | 558,000.00 |
| Sep 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 987,000.00 |
| Mar 31, 2025 | 804,000.00 |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 611,000.00 |
| Jun 30, 2024 | 2.80 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 2.53 Mn |
| Sep 30, 2023 | 3.31 Mn |
| Jun 30, 2023 | 3.87 Mn |
| Mar 31, 2023 | 804,000.00 |
| Dec 31, 2022 | 4.46 Mn |
| Sep 30, 2022 | 4.13 Mn |
| Jun 30, 2022 | 2.96 Mn |
| Mar 31, 2022 | 5.48 Mn |
| Dec 31, 2021 | 6.41 Mn |
| Sep 30, 2021 | 6.28 Mn |
| Jun 30, 2021 | 4.66 Mn |